Copy
View this email in your browser

Message from the CIRC President, Dr. Talat Bessissow

On behalf of the CIRC board, I would like to thank all members for their continued support. Our members have continued to be engaged in recruiting patients to research studies and proposing new and exciting ideas for future research studies. I would also like to thank all of our sponsors, previous and new, for their ongoing support of CIRC’s mission.
 
Now in our eighth year, CIRC has continued to grow and is currently running or completed ten multi-centre investigator-initiated studies designed to answer important clinical questions, including four multi-centred randomized controlled trials.  Three of these are at completion and CIRC’s first publications were in early 2023. We are continuing to make strides in our plans for rolling out a national research database and appreciate your input and insights on this front as we move long. Our project manager, Jane Castelli, and project coordinator, Nerissa Tahal, continue to be the glue that help hold our institution together and we are grateful for their hard work.
 
We we will also be launching CIRC’s second PIONEER grant in 2024 for $1,000,000 and are hopeful to continue making this a regular grant offered by CIRC in future years.
 
We are always open to new members, and if you have colleagues who you think would be interested to join, please get them in touch with us.  We look forward to meeting everyone virtually again in May, and in-person in November 2024 at Mentoring, for our upcoming meetings.

 

Talat Bessissow

Message from Crohn's and Colitis Canada
 
We will remember 2023 as the year of major impact achieved through the incredible trust and partnership that so many people in Canada have placed in Crohn’s and Colitis Canada for so many years.

The most significant news of the year was the Genetic, Environmental and Microbial (GEM) Project announcement on July 25. The team released a major finding that brings us closer to a cure for Crohn’s disease. After our 15-year investment – that will continue - the GEM team has discovered that the gut bacteria combination of those who develop Crohn’s disease is different from those who remain healthy – years before they develop Crohn’s.

Another milestone took place on June 1, when we issued our 2023 Impact of Inflammatory Bowel Disease in Canada report. We have published it every five years since 2007 and it is essential resource to understand the evolution of Crohn’s and colitis over time in our country – and the challenges we will face in future.

Another highlight of the year was our participation in the International Fashion Encounter (IFE) fashion show in Toronto that gave seven models with ostomies a chance to walk the runway.

What a year, we have much to celebrate. In partnership with you, we will continue to invest time, funds and expertise into achieving positive impact for everyone in Canada affected by Crohn’s and colitis.

Thank you for joining us on this journey to find the cures and improve the life of everyone affected by Crohn’s and colitis in Canada. Together, we are making tremendous progress thanks to the research community and our generous supporters. We are incredibly grateful for your contributions and look forward to sharing the impacts of CIRC with our IBD community.
 
To learn more or donate, visit crohnsandcolitis.ca.

Sincerely,

 

Lori Radke & Kate Lee

 
Lori Radke
President & CEO
Crohn's and Colitis Canada
Kate Lee
VP, Research and Patient Programs
Crohn's and Colitis Canada
THANK YOU TO OUR 2023 SPONSORS
CIRC's Second PIONEER Grant
CIRC's second PIONEER Grant Competition was announced during our annual meeting, and we would like to thank Takeda, Pfizer, and AbbVie for their generous sponsorship of nearly 1M in funding.

The PIONEER grant will support one study for 1M or two studies for 500k, and focus on high quality, impactful research in IBD. Priority will be given to:
  • Prospective RCT, but non-RCT designs will still be considered
  • Multi-site, multi-CIRC investigators
  • Demonstration of equity, diversity, and inclusive elements
The call for proposals will be made in late January 2024 with LOIs due in March. Full submissions will be invited in July and the final award announcement will be made in September.
The 2024 CIRC Executive Committee has been Announced!

The 2024 CIRC Executive Committee was recently announced during the November 4th, CIRC Annual Members Meeting.
President:
Vice President:
Treasurer:     
Director of Research:
Member at Large:
Member at Large:
Member at Large:
Past President:
Dr. Talat Bessissow
Dr. Chris Ma
Dr. Farhad Peerani
Dr. Harminder Singh
Dr. Cathy Lu
Dr. Peter Lakatos
Dr. Sanjay Murthy
Dr. Neeraj Narula
CIRC ENDORSED STUDIES

Tofacitinib in UC – Dr. Christopher Ma
Real World effective-ness and Safety of Tofacitinib for the Treatment of Patients with Moderate to Severe Ulcerative Colitis: A Multicentre Cohort Study

MRI Study – Dr. Jeffrey McCurdy
The role of MRI pelvis for predicting closure of perianal fistulas after treatment with anti-TNF alpha therapy in patients with Crohn’s disease

JUSTIFY – Dr. Talat Bessissow
Efficacy of Ustekinumab for the Treatment of Bio-Naïve Moderate-to-Severe Crohn’s Disease Patients: Real-World Data

FMT Pouchitis – Dr. Neeraj Narula
Fecal Microbiota Transplantation for Active Pouchitis: A Randomized Controlled Trial

TRIUMPH – Dr. Neeraj Narula & Dr. Tawyna Hansen
Tofacitinib by hospitalized acute severe Ulcerative Colitis Management

STATIC – Dr. Vipul Jairath
The STopping Aminosalicylate Therapy in Inactive Crohn’s Disease A Randomized, Open-label, Non-inferiority Trial

PROMOTE-UC – Dr. Greg Rosenfeld
Pro-Active Fecal Calprotectin Monitoring To Improve Patient Outcomes In Ulcerative Colitis: A Prospective Randomised Control Trial

Biosimilar – Dr. Waqqas Afif & Sasha Bernatsky
Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs

IBD-Dysplasia – Dr. Sanjay Murthy
A Randomized, Parallel-Group, Non-Inferiority Trial Comparing Random AND Targeted Biopsies to Targeted Biopsies Alone for Neoplasia Detection During Screening Colonoscopy in Adult Persons with Colonic Inflammatory Bowel Diseases: A Pilot Study
CANADIAN IBD TODAY


Visit our website at: http://circ-ccrm.ca/ 

If you have any questions, please email circ.ccrm@gmail.com


Copyright © 2023 CIRC, All rights reserved.


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.
Email
Twitter
Website






This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
CIRC · 2110-439 University Avenue · Toronto, ON M5G 1Y8 · Canada

Email Marketing Powered by Mailchimp